SILENCE THERAPEUTICS PLC
Develops treatments for rare genetic diseases.
Stock Performance Snapshot
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SLN
Oral Obesity Treatments: Beyond The Needle
Following successful Phase 3 trials for its oral weight-loss drug, orforglipron, Eli Lilly is positioned to enter the lucrative obesity treatment market. This development creates a new investment theme focused on pharmaceutical companies developing patient-friendly, oral alternatives to injectable GLP-1 therapies.
Published: August 27, 2025
Explore BasketPioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: July 21, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Verify the listing
Confirm the exchange, ISIN and full company name to avoid buying the wrong security; listings with similar tickers exist.
Check fundamentals
Review financials, market capitalisation and filings to understand the business; remember performance can vary and is not guaranteed.
Mind liquidity & fees
Look at trading volume and spreads — low liquidity can increase costs and volatility, so assess execution risk carefully.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
